Sickle cell disease in Sri Lanka: Clinical and molecular basis and the unanswered questions about disease severeity.

Background Though case reports and limited case series of Sickle cell disease in Sri Lanka have been reported previously, no attempt has been made hitherto to undertake a comprehensive genotypic-phenotypic analysis of this “rare” group of patients. Results All accessible Sickle cell disease patients, totaling 60, including, 51 Sickle β-thalassaemia and 9 homozygous sickle patients were enrolled from seven thalassaemia treatment centres between December 2016 - March 2019. The majority of patients were of Sinhalese ethnicity (n=52, 86.67%). Geographically, two prominent clusters were identified and the distribution of Sickle haemoglobin in the island contrasted markedly with the other haemoglobinopathies. 3/ 9 homozygous sickle patients and 3/ 51 Sickle β-thalassaemia patients were receiving regular transfusion. Joint pain was the commonest clinical presentation among all sickle cell disease patients (n=39, 65.0%). Dactylitis was significantly more common in homozygous sickle patients compared with the Sickle β-thalassaemia group ( p 0.034). Two genetic backgrounds sickle mutation were identified namely, Arab Indian and Benin. Among the regulators of Foetal hemoglobin in Sickle patients of the present study rs1427407 G>T seemed to be the most prominent modifier, with a significant association with Foetal haemoglobin levels ( p 0.04). Conclusions Overall, the clinical course of the Asian version of Sickle cell disease in Sri Lanka appears to be milder than that described in India.

G>T seemed to be the most prominent modifier, with a significant association with Foetal haemoglobin levels ( p 0.04).
Conclusions Overall, the clinical course of the Asian version of Sickle cell disease in Sri Lanka appears to be milder than that described in India.

Background
Sickle Cell Disease (SCD) is the collective term for a group of inherited disorders characterized by mutations in the gene encoding the β-haemoglobin subunit (HBB). The prevalence of the disease is high in sub-Saharan Africa, Middle East, India, Jamaica and Brazil. [1]. Sri Lanka is a multi-ethnic country with a population of 20.4 million, comprised of Sinhalese (74.9%), Tamils (15.2%), Moors (9.3%) and several other minor groups [2].
Sickle haemoglobin (Hb S) was first reported in the country among Sinhalese in 1962 in the Eastern province of the country. [3]. Even though Sri Lanka is geographically adjacent to India, where the prevalence of Hb S is high, particularly among tribal populations, the prevalence of Hb S in Sri Lanka is lower and is confined mainly to coastal areas [4]. No detailed descriptions of SCD in Sri Lanka are available in the literature, although there are several reports for some sporadic cases of SCD, including homozygous sickle cell anaemia (Hb SS), sickle-β thalassaemia (SBT) and Hb SD disease [5][6][7][8][9][10]. Currently, SCD patients in Sri Lanka are typically treated in either thalassaemia centres or general paediatric or medical wards. A recent island-wide hospital based epidemiological survey of haemoglobinopathies identified 1774 patients with a haemoglobinopathy. 51 of whom were sickle patients (un specified SCD), confirming that SCD is uncommon in Sri Lanka 2.8% (51/1774). The same survey identified significant inconsistencies in care of SCD patients between centres.
[11]. Genetic information including haplotype analysis for SCD in Sri Lanka is scarce, and has been reported for a single patient with SBT [12] only. Hence, in the present study we intend to describe the clinical picture of SCD patients in Sri Lanka, analyze its molecular basis, including the effects of genetic modifiers on the phenotype.

Study design and population
We conducted a cross-sectional study between December 2016 and March 2019 recruiting patients previously diagnosed with SCD from seven thalassaemia centres in Sri Lanka. The thalassaemia centres were located in the districts of Mahara, Kurunegala, Anuradhapura, Hambantota, Monaragala, Ampara and Batticaloa, All SCD patients were eligible for the study and there were no exclusion criteria. All patients were examined by the study physician and clinical details were obtained using a pre-tested interviewer-administered questionnaire.
Haematological and haemoglobin analyses A Five ml venous blood sample was collected into EDTA (Ethylenediaminetetraacetic acid) from each participant. Routine haematological measurements were conducted using a Coulter counter Ac•T 5diff OV (Beckman Coulter, Inc., Brea, California, United States). Haemoglobin phenotype was determined by capillary electrophoresis (CE) using Capillarys 2 flex piercing analyzer (Sebia, France). DNA for genetic analyses was extracted by QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) and stored at -20 0 C until further use.

Basic Genetic analyses
Classical β-globin haplotyping was performed. Six regions around and within the β globin gene cluster were amplified by the polymerase chain reaction (PCR), using primers from Integrated DNA Technologies, Inc., Iowa, United States. Primer sequences were those referenced by [13]. PCR products of each patient were treated with appropriate restriction enzymes (from Thermofisher scientific) according to manufactures instructions and the resulting fragments were separated on 2% agarose gel. Bands were visualized and photographed by UVP BioDoc-It® Imaging System. Six polymorphic restriction sites were studied; 5' to ε gene by Hind II, 5, to Gγ gene by Xmn I, within IVS 2 of the Gγ and Aγ genes by Hind III, 3' to ψβ by Hind II, and IVS 2 of the β gene by Ava II. When the Restriction Fragment Length Polymorphism (RFLP) pattern was heterozygous, the sickle haplotype was determined based on the assumption that common sickle haplotypes were present [14]. Common α + globin gene deletions (3.7 and 4.2 kb) were studied by multiplex GAP polymerase chain reaction [15]. Beta-thalassaemia mutations of the SBT patients were determined by Amplification Refractory Mutation System (ARMS) [16].

Genotyping of Foetal Haemoglobin (Hb F) modifiers among SCD patients
Four known Hb F modifiers (rs1427407 and rs6545816 in BCL11A, rs66650371 in HMIP-2A and rs9402686 in HMIP-2B) were genotyped by Taqman assay real time PCR using Viia 7 Applied Biosystems. One Hb F modifier (rs7482144 in Xmn1-HBG2) was genotyped by RFLP.
Homozygosity was confirmed in all 9 patients by typing the sickle mutation rs334 (T > A) at chr11:5227002 (GRCh38.p12) by NGS. There were 30 male and 30 female participants. SCD patients in the present study were living in 10 out of the 25 districts of Sri Lanka. Geographically, two prominent patient clusters were noted and the Southern cluster comprising Hambantota and Moneragala districts accounting for 27 (45.0%) SCD patients was the dominant cluster ( Fig. 1). The SCD patients comprised of three ethnic groups; 52 (86.67%) were Sinhalese, 5 (8.33%) were Moors and 3 (5.0%) were Tamils. Non-parametric statistical methods were used since data were not normally distributed.

Haematological data
Basic haematological parameters of those who had not received a blood transfusion in the three months prior to blood sampling are summarized in Table 1. Hb A2 levels were significantly lower among Hb SS group than SBT (p < 0.001) group. Conversely, MCV, MCH and MCHC values were all significantly higher among Hb SS group (p < 0.001). Reticulocyte count was also significantly higher in Hb SS group (p 0.013) suggesting increased rates of haemolysis compared to SBT.  rs28440105, rs10128556 and rs968857) in 9 Hb SS patients as described previously [17]. When looking at the genetic variants that moderate Hb F levels, rs6545816 in BCL11A was found at the highest allele frequency (88%) followed by rs7482144 in Xmn I-HBG2 (47%) (

Discussion
Our study is the first description of the genotypic and phenotypic associations of SCD in Sri Lanka.
Haplotype data in our present study sheds new light on the genetic background of Hb S in Sri Lanka.
Both AI and Benin haplotypes of Hb S are common in Saudi Arabia [18,19]. The presence of AI and Benin haplotypes of Hb S in Sri Lanka suggests that occurrence of Hb S in Sri Lanka is more likely to have originated from Arab migrations than African settlings. Historical records also indicate the existence of Arab settlements near coastal towns of Beruwala, Colombo, Chilaw, Galle, Mannar, Puttalam and Trincomalee by 9th century A.D. [20]. In the present study most of the SCD patients recruited were living fairly close to some of above mentioned coastal areas.
Joint pain was the most common clinical feature observed in both Hb SS (77.78%) and SBT (62.75%) patients. Joint pains are not uncommon among sickle patients in the Indian subcontinent. A recent study from Madhya Pradesh, Central India reported that the incidence of joint pain is over 80% in both was not present in any participants in our study. Requirement for regular blood transfusions was higher among Hb SS (33.33%) than SBT (5.88%) patients in the present study. These findings differ from a study reported from Madhya Pradesh (India) in which 16.1% of Hb SS and 17.4% of SBT patients were on regular blood transfusion [21]. Furthermore, twelve (23.53%) SBT patients had never received a transfusion in their lifetime. As the indication for blood transfusions were very often physician initiated and there was no defined rationale, these observations need to be interpreted with caution, and suggests the need for clear guidelines on the management of SCD in Sri Lanka, including the use of transfusion.
Only two cases of avascular necrosis of the hip were reported in the present study, which is in contrast to eastern Indian SCD patients, in whom incidences over 10% have been reported across several age groups [25]. Priapism and leg ulcers were not found in our study. There were no deaths in any of the SCD patients reported during the period of observation.
Hb F plays a significant role in ameliorating complications is SCD [26]. In the present study, in patients who were not on transfusion, mean Hb F concentrations were 24.4% and 23.0% in Hb SS and SBT patients, respectively. These values are in accordance with the observations from the Maharashtra (India) but are higher than the values observed in Madhya Pradesh (India) [21,24]. The Hb F levels are much higher than those found in SCD patients of Sub-Saharan African origin, and levels greater than 20% would typically be associated with less severe clinical picture. Hb F boosting allele "C" of rs6545816 was detected at a much higher frequency in Sri Lankan patients than in patients from the United Kingdom (34%), Tanzania (36%) and Nigeria (35%) [27,28]. Furthermore, "T" allele of rs1427407 was significantly associated with high Hb F levels (p = 0.04). The presence of common α + gene deletions was surprisingly low in this study. This is in contrast with observations in Western Indian SCD patients in whom the prevalence of α gene deletions was 29/51;56.8% [29].
One of the most notable observational findings of our study was the gross inconsistency in the clinical management of SCD patients across the different centres across Sri Lanka. Usage of hydroxyurea was not consistent among sickle patients in these centres. Equally, the practice of blood transfusions was also very variable, reflecting perhaps the lack of familiarity in the management of the disease by the attending medical teams and the need for national guidelines on the management of patients with SCD.

Conclusions
Overall, though the numbers may be limited the clinical course of the Asian version of SCD in Sri Lanka appears to be milder than that described from India. High HbF levels are common and deletional α thalassaemia rarer. The natural selection, early migratory patterns of Arabs and settlements may explain why SCD is found mostly in coastal regions and low lands of Sri Lanka. We plan to undertake further work to elucidate the causative elements responsible for the milder appearance of SCD in Sri Lanka.

Ethics approval and consent to participate
Ethical approval for the study was obtained from Faculty of Medicine, University of Kelaniya, Sri Lanka (P/01/01/2016). Informed written consents form adult SCD patients and assents from the parents of the participating SCD children were obtained before enrollment for the present study.

Consent for publication
Not applicable

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.  Locations from which SCD patients were reported in present study (each dot represents one patient) Figure 2 Allelic discrimination of the marker Hb F marker rs6545816 of SCD patients of the present study.